Form 4: MAIA Biotechnology Director Acquires Stock Options
SEC Filing
Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., reported the acquisition of stock options on October 1, 2024.
Summary
- On October 1, 2024, Jean-Manasse Theagene, a director of MAIA Biotechnology, Inc., filed a Form 4.
- The form reports the acquisition of 7,232 stock options with an exercise price of $2.81.
- These options were granted on September 30, 2024, under the company's 2021 Equity Incentive Plan.
- The options vest immediately and are exercisable from the grant date, expiring on September 30, 2034.
- Theagene directly owns these options.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard regulatory filing related to stock option grants. The director's acquisition could be interpreted slightly positively, but it's not a major event.
Positives
- A director's acquisition of stock options can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency regarding insider transactions in publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of grant for the stock options under the 2021 Equity Incentive Plan. |
| 09/30/2024 | Stock options vest 100% on this date. |
| 09/30/2034 | Expiration date of the stock options. |
| 10/01/2024 | Date of the transaction and filing of Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.